[의학신문·일간보사=김자연 기자] GSKgo RSV vaccine RSVPreF3 OAsuccessful about 3By disclosing the clinical trial results, the company spurred competition in the future market..
GSKAccording to 60for ages 3 and older 3As a result of the phase test, the vaccine 82.6%lower respiratory tract infection of(LRTD) showed a preventive effect.
In addition, the effect on severe infection by at least two respiratory signs or investigator assessment was not 94.1%appeared as.
In addition, the heart·Respiratory and Metabolism·For participants with endocrine disorders, etc. 94.6%, 70about the 93.8%showed the effect of.
This effect is RSV-Ame RSV-Bfor each 84.6%, 80.9%was consistent, and side effects were mild. GSKsaid it plans to apply for approval at the end of this year..
Previously, Pfizer RSVpreF about the vaccine 60more than a target 3In a phase clinical trial, lower respiratory tract infections defined as two or more symptoms 66.7%, Severe, defined as three or more symptoms 85.7%announced the effect of.
In this regard, Morgan Stanley said that it is difficult to make a direct comparison of the two vaccines, but overall GSKof the data appeared to be more robust..
Jeffreys responded to this with regard to old age. GSKof RSV Vaccine sales increase 25A more specific definition of severity or safety between the two vaccines in the future, Additional data on tolerability comparisons and persistence will be key issues, he added..
MeanwhileGSKearlier this year for pregnant women 3The phase-in clinical trial was stopped as a result of safety evaluation by an independent data monitoring committee..
in addition NOT A WORDand modernado RSV vaccine 3It is in phase clinical trial and results are expected to be released at the end of this year, and Sanofi is also pursuing development..
As a result, Credit Suisse RSV the vaccine market 60The United States, which could reach billions of dollars CDC Health authorities will focus on the prevention of hospitalization when selecting a vaccine. GSKautumn market medicine 1/3predicted to take.